ArticleGastroenterology research and practice2017
Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.
Article in Gastroenterology research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Visceral medicine · 2021Pooled it
- Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review.World journal of gastroenterology · 2021Pooled it
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.The American journal of gastroenterology · 2019Pooled it
- Effect of montelukast on remission maintenance in patients with ulcerative colitis: a Randomized, double-blind controlled clinical trial.BMC gastroenterology · 2025Trial
- Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study.Inflammatory bowel diseases · 2026Article
- Serum amyloid a as a high-resolution indicator of mucosal healing in ulcerative colitis.Crohn's & colitis 360 · 2026Article
- Comparative effectiveness of mirikizumab and risankizumab in patients with ulcerative colitis: A propensity-matched cohort study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Anxiety and depression in newly diagnosed patients with inflammatory bowel disease (the IBSEN III study) compared with the general population in Norway.Journal of Crohn's & colitis · 2026Article
- Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases.Scientific reports · 2026Article
- Serum cytokine inflammatory profile in children with ulcerative colitis during 6-month follow-up.Scientific reports · 2025Article
- Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis; A Placebo Randomized Controlled Trial.Life (Basel, Switzerland) · 2025Article
- Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach.Alimentary pharmacology & therapeutics · 2025Review
- Crohn's disease and clinical management today: How it does?World journal of methodology · 2023Review
- Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III Study.BMC gastroenterology · 2023Article
- Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study.Intestinal research · 2022Article
- Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.Life (Basel, Switzerland) · 2021Review
- Article
- Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.Journal of pediatric gastroenterology and nutrition · 2019Observational
- Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.World journal of gastroenterology · 2019Observational
- Role of indoleamine 2,3-dioxygenase in pathology of the gastrointestinal tract.Therapeutic advances in gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMucosal healing has become the new goal of treatment in ulcerative colitis. Fecal calprotectin has been demonstrated to differentiate between mucosal inflammation and mucosal healing. With this project, we investigated whether a reduction in f-calprotectin to <250 MATERIAL AND
methodsAfter a baseline colonoscopy, 20 patients with active ulcerative colitis were followed with consecutive fecal calprotectin monthly until two measurements of fecal calprotectin < 250
resultsA total of 16 patients achieved fecal calprotectin < 250
conclusionsFecal calprotectin <250
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.